Q1 2025 Tenon Medical Inc Earnings Call Transcript
Key Points
- Tenon Medical Inc (TNON) reported a 1% increase in revenue for the first quarter of 2025 compared to the same period in 2024, indicating steady growth.
- The company is preparing for the full commercial launch of the new Catamaran SE platform, which is expected to enhance its product offerings and drive growth.
- The FDA cleared the Catamaran SI Joint Fusion System for an extended indication, allowing it to augment thoracal lumbar fusion, opening new market opportunities.
- Tenon Medical Inc (TNON) received two European patents for its Catamaran SI joint fixation device, strengthening its intellectual property portfolio.
- The company raised $7.1 million in gross proceeds from equity financing, boosting its cash balance to $10.3 million, providing a strong cash runway for growth initiatives.
- Gross profit decreased to $323,000 or 44% of revenue in Q1 2025, compared to $470,000 or 65% of revenue in Q1 2024, indicating a decline in gross margin.
- Operating expenses remained flat at $4 million, with anticipated increases in sales and marketing expenses expected in future quarters.
- The company reported a net loss of $3.6 million for Q1 2025, consistent with the same period in 2024, and expects to incur additional losses in the future.
- Reimbursement pre-authorization headwinds impacted revenue growth, although these are expected to be transient.
- The company faces challenges in coding clarity, which affects the pre-authorization process and could delay revenue growth.
Greetings, and welcome to the Tenon Medical first-quarter 2025 financial results and corporate update conference call. As a reminder, this call is being recorded. Your hosts today are Steve Foster, President and Chief Executive Officer; and Kevin Williamson, Chief Financial Officer. Mr. Foster and Mr. Williamson will present results of operations for the first quarter ended March 31, 2025, and provide a corporate update.
A press release detailing these results was released today and is available on the Investor Relations section of our company's website, www.tenonmed.com. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates and other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
